Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Compugen Ltd Logo

ARKG Holdings of Compugen (CGEN) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
January 5, 2022BUY71.500k0.0061%ARKG
January 4, 2022BUY23.216k0.002%ARKG
January 3, 2022BUY14.413k0.0012%ARKG
December 30, 2021BUY66.398k0.0058%ARKG
January 13, 2021SELL200.000ARKG

Key Statistics

Upcoming EarningsSee Full Calendar
DateFebruary 23, 2022(Est)Revenue
Expected$3.00m
Actual▫️
EPS
Expected-$0.10
Actual▫️
🕵🏼Found In🏷Last Price
IZRLARKKARKG$3.47
⚖️Weighting🧢Market Cap
0.31%$302.10m
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
4737.76
🏋️‍♀️Weight Rank Across All Funds🌏Country
88🇮🇱Israel
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$9.404%
Description
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
Website
www.cgen.com

Research Notes and Commentary for CGEN